Involvement of the p16INK4 (CDKN2) gene in familial melanoma

Melanoma Research

Volumn 6, Issue 2, 1996, Pages 139-145

  Naylor, M F ^a   Everett, M A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

CDKN2; cell cycle; cyclin dependent kinase inhibitors; familial melanoma; p16INK4; tumor suppressors

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER FAMILY; CANCER GENETICS; CELL CYCLE; CLINICAL ARTICLE; ENZYME INHIBITION; FAMILIAL CANCER; GENE MUTATION; GENETIC LINKAGE; HUMAN; HUMAN CELL; MELANOMA; MOLECULAR GENETICS; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

EID: 0029739412     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199604000-00009     Document Type: Article

References (93)

1. Norris W. Case of fungoid disease. Edin Med Surg J 1820; 16: 562-565.
2. Slade J, Marghoob AA, Salopek TG, et al. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995; 32: 479-494.
3. Cawley EP. Genetic aspects of malignant melanoma. Arch Dermatol Syphillol 1951; 65: 440-45.
4. Meyer LJ, Zone JH. Genetics of cutaneous melanoma. J Invest Dermatol 1994; 103: 112S-116S.
5. Greene MH, Goldin LR, Clark WHJ, et al. Familial cutaneous melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci 1983; 80: 6071-6075.
6. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320: 1367-1372.
7. Cannon-Albright LA, Goldgar DE, Wright EC, et al. Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Am J Hum Genet 1990; 46: 912-918.
8. Nancarrow DJ, Palmer JM, Walters MK, et al. Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics 1992; 12: 18-25.
9. Kefford RF, Salmon J, Shaw HM, et al. Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 1991; 51: 45-55.
10. van Haeringen A, Bergman W, Nelen MR, et al. Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics 1989; 5: 61-64.
11. Goldstein AM, Dracopoli NC, Ho EC, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 1993; 52: 537-550.
12. Gruis NA, Sandkuijl LA, Weber JL, et al. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 1993; 3: 271-277.
13. Goldstein AM, Dracopoli NC, Engelstein M, et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 1994; 54: 489-496.
14. Skolnick MH, Cannon-Albright LA, Kamb A. Genetic predisposition to melanoma. Eur J Cancer 1994; 30A: 1991-1995.
15. Piepkorn MW. Genetic basis of susceptibility to melanoma. J Am Acad Dermatol 1994; 31: 1022-1039.
16. Nancarrow DJ, Walker GJ, Weber JL, et al. Linkage mapping of melanoma (MLM) using 172 microsatellite markers. Genomics 1992; 14: 939-947.
17. Knudson AGJ. The genetics of childhood cancer. Cancer 1975; 35: 1022-1026.
18. Fearon ER. Genetic alterations underlying tumorigenesis. Cancer Surv 1992; 12: 119-136.
19. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
20. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088-2090.
21. Lundberg C, Skoog L, Cavenee WK, et al. Loss of heterozygosity in human ductal breast tumors indicates a recessive mutations on chromosome 13. Proc Natl Acad Sci 1987; 84: 2372-2376.
22. Genome Data Base. Johns Hopkins University, 1985.
23. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
24. Weaver-Feldhaus J, Gruis NA, Neuhausen S, et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci 1994; 91: 7563-7567.
25. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancer Nature 1994; 368: 753-756.
26. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
27. Zhang S-Y, Klein-Szanto AJP, Sauter ER, et al. Higher frequency of alteration in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994; 54: 5050-5053.
28. Spruck CH, Gonzalez-Zuleta M, Shibata A, et al. p16 gene in uncultured tumours. Nature 1994; 370: 183-184.
29. Wainwright B. Familial melanoma and p16 - a hung jury. Nature Genetics 1994; 8: 3-5.
30. Bonetta L. Open questions on p16. Nature 1994; 370: 180.
31. Lydiatt WM, Murty VV, Davidson BJ, et al. Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes, Chromosomes Cancer 1995; 13: 94-98.
32. Gruis NA, Weaver-Feldhaus J, Liu Q, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995; 146: 1199-1206.
33. Yeager T, Stadler W, Belair C, et al. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 1995; 55: 493-497.
34. Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions with human chromosome band 9p21 in melanoma. Proc Natl Acad Sci 1992; 89: 10557-10561.
35. Walker GJ, Palmer JM, Walters MK, et al. Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions. Oncogene 1994; 9: 819-824.
36. Isshiki K, Seng BA, Elder DE, et al. Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene 1994; 9: 1649-1653.
37. Holland EA, Beaton SC, Edwards BG, et al. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 1994; 9: 1361-1365.
38. Caldas C, Hahn SA, Cost LTD, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics 1994; 8: 27-32.
39. Mori T, Miura K, Aoki T, et al. Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396-3398.
40. Hayashi N, Sugimoto Y, Tsuchiya E, et al. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small lung carcinomas. Biochem Biophys Res Commun 1994; 202: 1426-1430.
41. Knudson AGJ, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci 1975; 72: 5116-5120.
42. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nature Genetics 1994; 8: 15-21.
43. Walker GJ, Hussussian CJ, Flores JF, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Molec Genet 1995; 4: 1845-1852.
44. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genetics 1994; 8: 22-26.
45. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995; 11: 136-140.
46. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
47. Hirai H, Roussel MF, Kato J, et al. Novel INK4 proteins, p19 and p18 are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Molec Cell Biol 1995; 15; 2672-2681.
48. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995; 55: 2266-2269.
49. Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res 1994; 54: 5816-5820.
50. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16(MTS1) locus. Cancer Res 1995; 55: 2988-2994.
51. Halevy O, Novitch B, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018-1021.
52. Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-1027.
53. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 1995; 270: 18195-18197.
54. Peters G. Stifled by inhibitions. Nature 1994; 371: 204-205.
55. Guan KL, Jenkens CW, Li Y, et al. Growth suppression by p18, a p16INK4MTS1- and p14INK4MtS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Develop 1994; 8: 2939-2952.
56. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
57. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994; 54: 440-452.
58. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55 505-509.
59. Li Y, Nichols MA, Shay JW, et al. Transcriptional regression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994; 54: 6078-6082.
60. Aagaard L, Lukas J, Bartkova J, et al. Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 1995; 61: 115-120.
61. Parry D, Bates S, Mann DJ, et al. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 1995, 14: 503-511.
62. Schmidt EE, Ichimura K, Reifenberger G, et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321-6324.
63. Sanders BM, Jay M, Draper GJ, et al. Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 1989; 60: 358-365.
64. Albert LS, Sober AJ, Rhodes AR. Cutaneous melanoma and bilateral retinoblastoma. J Am Acad Dermatol 1990; 23: 1001-1004.
65. Traboulsi EI, Zimmerman LE, Manz HJ. Cutaneous malignant melanoma in survivors of heritable retinoblastoma Arch Ophthalmol 1988; 106: 1059-1061.
66. Greene MH, Tucker MA, Clark WHJ, et al. Hereditary melanoma and the dysplastic nevus syndrome: the risk of cancers other than melanoma. J Am Acad Dermatol 1987; 16: 792-797.
67. Arap W, Nishikawa R, Furnari B, et al. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995; 55 1351-1354.
68. Jin X, Nguyen D, Zhang W-W, et al. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 1995; 55: 3250-3253.
69. Walker GJ, Palmer JM, Walters MK, et al. A genetic model of melanoma tumorigenesis based on allelic losses. Genes, Chromosomes Cancer 1995; 12: 134-141.
70. Reed JA, Loganzo Jr F, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713-2718.
71. Moulton T, Samara G, Chung WY, et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995; 146: 613-619.
72. Nishikawa R, Furnari FB, Lin H, et al. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res 1995; 55: 1941-1945.
73. Okamoto A, Hussain SP, Hagiwara K, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55: 1448-1451.
74. Li YJ, Hoang-Xuan K, Delattre JY, et al. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 1995; 11: 597-600.
75. Ohnishi H, Kawamura M, Ida K, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995; 86: 1269-1275.
76. Ueki K, Rubio MP, Ramesh V, et al. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Molec Genet 1994; 3: 1841-1845.
77. Hebert J, Cayuela JM, Berkeley J, et al. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994; 84
78. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 1994; 54: 5269-5272.
79. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994; 54: 6338-6339.
80. Otsuki T, Clark HM, Wellmann A, et al. Involvement of CDKN2 (p16INK44/MTS1) and p15INK4B/MTS2) in human leukemias and lymphomas. Cancer Res 1995; 55: 1436-1440.
81. Okuda T, Shurtleff SA, Valentine MB, et al. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995; 85: 2321-2330.
82. Kai M, Arakawa H, Sugimoto Y, et al. Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. Jpn J Cancer Res 1995; 86: 249-251.
83. Olopade OI, Pomykala HM, Hagos F, et al. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci 1995; 92: 6489-6493.
84. Filmus J, Kerbel RS. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol 1993; 5: 123-129.
85. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncogen 1993; 4: 493-540.
86. Rodeck U, Bossler A, Graeven U, et al. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 1994; 54: 575-581.
87. Rogers SL, Gegick PJ, Alexander SM, et al. Transforming growth factor-beta alters differentiation in cultures of avian neural crest-derived cells: effects on cell morphology, proliferatiion, fibronectin expression, and melanogenesis. Devel Biol 1992; 151: 192-203.
88. Bennicelli JL, Guerry DT. Production of multiple cytokines by cultured human melanomas. Exp Dermatol 1993; 2: 186-190.
89. Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. In: Clark WH, Goldman L and Mastrangelo M, eds. Human Malignant Melanoma, New York: Grune and Stratton, 1979: 139-166.
90. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 1994; 54: 6041-6044.
91. Liu L, Lassam NJ, Slingerland JM, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995; 11: 405-412.
92. Chan FKM, Zhang J, Cheng L, et al. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Molec Cell Biol 1995; 15: 2682-2688.
93. Datto MB, Li Y, Panus JF, et al. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci 1995; 92: 5545-5549.